Cantor Fitzgerald Brokers Cut Earnings Estimates for VERA

Key Points

• Cantor Fitzgerald has significantly revised down its FY2025 earnings estimates for Vera Therapeutics from ($2.79) to ($4.40) per share, while maintaining an "Overweight" rating with a price target of $100.00.
• The company's recent quarterly earnings report revealed an EPS of (1.20), falling short of analysts' consensus forecast of (0.82).
• Insider activity showed Director Patrick G. Enright increasing his stake by purchasing 209,393 shares at an average price of $20.87, boosting his total ownership to approximately $74.5 million.

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Wednesday, August 6th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($4.40) per share for the year, down from their previous forecast of ($2.79). Cantor Fitzgerald has a "Overweight" rating and a $100.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Cantor Fitzgerald also issued estimates for Vera Therapeutics' FY2026 earnings at ($4.42) EPS.

A number of other analysts have also recently weighed in on VERA. Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Wedbush lowered their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Scotiabank reissued an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Wolfe Research reaffirmed a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $85.00 price objective (up previously from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $63.00.

Vera Therapeutics Price Performance

Shares of VERA traded up $0.50 during mid-day trading on Friday, reaching $20.67. The company had a trading volume of 870,418 shares, compared to its average volume of 1,287,593. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. The company has a market capitalization of $1.32 billion, a P/E ratio of -5.77 and a beta of 1.17. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $51.61. The company's 50-day moving average is $22.74 and its 200-day moving average is $24.92.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same period in the previous year, the company posted ($0.62) EPS.

Institutional Trading of Vera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $56,000. Quarry LP grew its holdings in Vera Therapeutics by 25.0% during the 1st quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after acquiring an additional 500 shares during the period. AlphaQuest LLC raised its position in shares of Vera Therapeutics by 404.7% during the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company's stock valued at $96,000 after acquiring an additional 3,213 shares during the last quarter. Fifth Third Bancorp acquired a new position in shares of Vera Therapeutics in the 2nd quarter valued at $102,000. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after purchasing an additional 639 shares during the period. 99.21% of the stock is owned by institutional investors.

Insider Transactions at Vera Therapeutics

In other news, Director Patrick G. Enright acquired 209,393 shares of the firm's stock in a transaction on Monday, June 23rd. The shares were purchased at an average cost of $20.87 per share, for a total transaction of $4,370,031.91. Following the transaction, the director owned 3,569,522 shares of the company's stock, valued at approximately $74,495,924.14. This represents a 6.23% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 16.30% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.